Avita Therapeutics (AVH.AU) shares are soaring 11.20% in Thursday's trading session, following the announcement of the company's plans to present groundbreaking clinical data at the American Burn Association (ABA) 2025 Annual Meeting. The significant uptick in share price reflects investors' positive reaction to the company's expanding evidence base and commitment to advancing burn and wound care treatments.

AVITA Medical, Inc., the parent company of Avita Therapeutics, revealed that it will showcase 16 abstracts at the ABA 2025 conference, highlighting real-world findings and clinical innovations across its expanded portfolio. The presentations will feature data on the company's key products, including RECELL, Cohealyx, and PermeaDerm, demonstrating AVITA's growing influence in the therapeutic acute wound care sector.

Investors appear particularly encouraged by the breadth and depth of the data being presented. Key highlights include a large-scale retrospective analysis of over 6,000 patients treated with RECELL, new pre-clinical studies on Cohealyx, and clinical trials demonstrating the efficacy of PermeaDerm. These presentations not only showcase the company's innovative technologies but also provide evidence of their real-world impact on patient outcomes, potentially driving further adoption and market expansion. The strong market reaction suggests that shareholders anticipate these developments to translate into increased sales and market share for Avita Therapeutics in the coming months.